

## Block view of the study programme

Or Th Pr Au Cr

### Bloc 1 du programme de l'année

#### Compulsory courses

		Q1				
PHIN2004-1	<i>Active substances</i>					<b>6</b>
	- <i>Substances issues de recherches pharmacochimiques, part a</i> - Bernard PIROTTE	10	-	-		
	- <i>Substances issues de recherches pharmacochimiques, part b</i> - Françoise DUFRASNE	5	-	-		
	- <i>Substances issues des biotechnologies</i> - David VERMIJLEN	15	-	-		
	- <i>Substances d'origine naturelle, part a</i> - Joëlle QUETINLECLERCQ	5	-	-		
	- <i>Substances d'origine naturelle, part b</i> - Pierre DUEZ	5	-	-		
	- <i>Produits radiopharmaceutiques</i> - Ghanem GHANEM	10	-	-		
PHIN2008-2	<i>Clinical viewpoints</i>					<b>6</b>
	- <i>Métabolisme des médicaments et paramètres pharmacocinétiques</i> - Roger VERBEEK	20	-	-		
	- <i>Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques)</i> - Régis RADERMECKER	15	-	-		
	- <i>Information et pharmacovigilance</i> - Raphaël DENOZ	10	-	-		
PHIN2013-2	<i>Quality assurance and pharmaceutical management</i>					<b>7</b>
	- <i>Principles of pharmaceutical management</i> - JeanMichel VAN DER HOFSTADT	10	-	-		
	- <i>Quality assurance, part a : basic concepts and quality assurance organisation</i> - Jean SCOUVART	20	-	-		
	- <i>Quality assurance, part b : Analytical technology of procedures and risk analysis</i> - Xavier MARCELIS	7,5	-	-		
	- <i>English applied to the pharmaceutical industry</i> - Jacques POUPAERT, Nevin SERBEST	20	-	-		
	- <i>Pharmaceutical marketing</i> - Vincent BIERLAIRE	7,5	-	-		
PHIN2033-1	<i>Industrial pharmaceutical technology</i>					<b>8</b>
	- <i>Industrial pharmaceutical microbiology</i> - Véronique FONTAINE	15	-	-		
	- <i>Preformulation and selection of galenical forms</i> - Karim AMIGHI	15	-	-		
	- <i>Industrial production of galenical forms</i> - Brigitte EVRARD	15	-	-		
	- <i>Industrial production of biomolécules</i> - Philippe LEVEQUE, Rita VAN BEVER	15	-	-		
	- <i>Industrial aspects of technological development including packaging</i> - Laurence DENIS	10	-	-		
PHIN2023-1	<i>Drug analysis</i>					<b>7</b>
	- <i>Analytical methods and pharmaceutical and biopharmaceutical control, part a</i> - JeanMichel KAUFFMAN, Pierre VAN ANTWERPEN	10	-	-		
	- <i>Analytical methods and pharmaceutical and biopharmaceutical control, part b</i> - Marianne FILLET	10	-	-		
	- <i>Methods in pharmaceutical and biopharmaceutical analysis, part a : Validation and qualification of equipment</i> - Philippe HUBERT, Roland MARINI DJANG'EING'A	15	-	-		
	- <i>Methods in pharmaceutical and biopharmaceutical analysis, part b : Process analytical technology</i> - Philippe HUBERT, Eric ZIEMONS	5	-	-		
	- <i>Statistical methods applied to the pharmaceutical industry</i> - Bernadette GOVAERTS	15	-	-		
	- <i>Experimental planning and "quality by design"</i> - Bruno BOULANGER	10	-	-		
PHIN2029-2	<i>Regulation and the medical-social environment</i>					<b>8</b>
	- <i>Economic aspects of drug development</i> - Dominique MARTIN	10	-	-		
	- <i>Legislation and procedures applied to pharmaceutical industry, part a : legislation</i> - Catherine DRUEZ	10	5	-		
	- <i>Legislation and procedures applied to pharmaceutical industry, part b : patents and protection</i> - Patrick DI STEFANO	5	-	-		
	- <i>Macroeconomic environment and pharmaco-economics</i> - Pierre DUEZ	10	-	-		

	- <i>CTD File (Common Technical Document)</i> - JeanAntoine DE MUYLDER	15	-	-	
	- <i>Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files</i> - Sonia BEKEN	15	-	-	
	- <i>Regulations of preclinical and clinical studies, part b : clinical studies</i> - A LENAERS	5	-	-	
	- <i>Regulations of preclinical and clinical studies, part c : pediatric studies</i> - Daniel BRASSEUR	2,5	-	-	
	- <i>Specific regulatory issues, part a : medicine and herbal dietary supplement</i> - Michel FREDERICH	5	-	-	
	- <i>Specific regulatory issues, part b : Preformulation and galenical development documentation</i> - Francis VANDERBIST	5	-	-	
PHIN2032-1	<i>Visits and seminars organised in the pharmaceutical industry</i> - Françoise DUFRASNE, Brigitte EVRARD, Rita VAN BEVER - [77,5h Vis.]	-	-	[+]	<b>3</b>
MTFE2000-1	<i>Final work</i> - Françoise DUFRASNE, Brigitte EVRARD, Rita VAN BEVER	-	-	-	<b>15</b>